PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow

Despite the great success of immune-checkpoint inhibitor (ICI) treatment for multiple cancers, evidence for the clinical use of ICIs in acute myeloid leukemia (AML) remains inadequate. Further exploration of the causes of immune evasion in the bone marrow (BM) environment, the primary leukemia site,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ling, Liu, Lian, Yao, Danlin, Zeng, Xiangbo, Zhang, Yikai, Lai, Jing, Zhong, Jun, Zha, Xianfeng, Zheng, Runhui, Lu, Yuhong, Li, Minming, Jin, Zhenyi, Hebbar Subramanyam, Sudheendra, Chen, Shaohua, Huang, Xin, Li, Yangqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416522/
https://www.ncbi.nlm.nih.gov/pubmed/34490086
http://dx.doi.org/10.3389/fonc.2021.686156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416522/
https://www.ncbi.nlm.nih.gov/pubmed/34490086
http://dx.doi.org/10.3389/fonc.2021.686156

Ejemplares similares